Health service and government policies on the licensing, provision and reimbursement of oral pre-exposure prophylaxis (PrEP). Expert guidelines, based on research evidence, to help clinicians provide care to PrEP users.

PrEP policies and guidelines: latest news

PrEP policies and guidelines features

PrEP policies and guidelines news from aidsmap

More news

PrEP policies and guidelines news selected from other sources

  • HIV prevention pill to get insurance benefit in Korea

    The government has decided to allow reimbursement for Gilead’s Truvada (tenofovir disoproxil fumarate/emtricitabine) for pre-exposure prophylaxis (PrEP). The Ministry of Health and Welfare on Tuesday said it would grant insurance benefit for Truvada HIV-1 PrEP used for people who are negative in HIV-1 infection but at high risk due to sex with an HIV-positive partner, starting from June 7.

    02 June 2019 | Korea Biomedical Review
  • California may make anti-HIV drug available without prescription for 30 days

    Democratic Sen. Scott Wiener has proposed a bill that would allow people to receive their first 30 days of PrEP over the counter if they first receive counseling and an HIV test. But the bill faces opposition from the California Medical Association, which represents doctors, and major insurance companies.

    02 June 2019 | San Francisco Chronicle
  • UK's biggest sexual health clinic has just dropped its PrEP prices

    PrEP has become more affordable at London’s leading sexual health clinic. The 56 Dean Street clinic opened its PrEP Shop in February last year and provides the HIV preventative medication for those eligible for NHS care. It will cost as little as £17.50 per month.

    02 June 2019 | Gay Star News
  • Is Off-Label HIV Prevention Better Than None?

    Rather than prescribe F/TDF as PrEP, Michael Saag, MD said, prescribers should sidestep the brand-name product and instead give their PrEP-eligible patients a generic HIV drug combination that uses lamivudine (3TC) with TDF.

    31 May 2019 | MedPage Today (requires free registration)
  • The truth is you can afford the medication that prevents HIV. Here’s how.

    It’s not the cost of PrEP that keeps more patients from accessing it; it’s the lack of awareness and the daunting nature of our complicated healthcare system.

    24 May 2019 | LGBTQ Nation
  • A Review of the Congressional Hearing on HIV Drug Pricing

    In an effort to best encapsulate the remarks of many of the members of the House and the powerful testimony of the HIV advocates present at the recent Congressional hearing on drug pricing around Gilead Sciences’ HIV prevention drug Truvada, we thought it was best to provide you with their own words.

    23 May 2019 | POZ
  • Republicans defend drug company in spotlight over HIV medication prices

    Republican members of Congress defended Gilead, the leading manufacturer of HIV drugs in the U.S., during a testy hearing Thursday as Democrats blasted the company over the prices of its products.

    17 May 2019 | The Hill
  • A Leading HIV Drug Is Way Overpriced in the U.S.

    A House hearing over the price of Truvada shows a particularly glaring example of a rampant industry practice.

    17 May 2019 | Bloomberg
  • Alexandria Ocasio-Cortez Tells Gilead CEO That ‘People Are Dying’ Because His Company Charges Nearly $2,000 For Drug That Sells For $8 In Australia

    "I think it's important here that we notice that we the public, we the people, developed this drug. We paid for this drug, we led and developed all the patents to create PrEP [the commonly known name for Truvada] and then that patent has been privatized, despite the fact that the patent is owned by the public, who refused to enforce it," the representative said. “There’s no reason this should be $2,000 a month. People are dying because of it,” she added.

    17 May 2019 | Newsweek
  • Statement on Gilead’s Announcement of PrEP Donation

    Gilead’s donation is an acknowledgment that there is a huge issue with PrEP access in America, as in many parts of the world. We welcome this indication that the company grasps the gravity of the situation. However, we urgently need a lower price for all. It’s disappointing that even this small step has taken so long.

    14 May 2019 | AVAC
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.